{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:59:37Z","timestamp":1789880377350,"version":"4.0.1"},"reference-count":76,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L008246"],"award-info":[{"award-number":["MR\/L008246"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/P010849\/1"],"award-info":[{"award-number":["BB\/P010849\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0007373","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T14:28:57Z","timestamp":1558621737000},"page":"e0007373","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0919-3745","authenticated-orcid":true,"given":"Paula","family":"MacGregor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Gonzalez-Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumatta","family":"Jobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Sandercock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-8019","authenticated-orcid":true,"given":"Olivia J. S.","family":"Macleod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Van Bocxlaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"D\u2019Hooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2936-0515","authenticated-orcid":true,"given":"Arnaud","family":"Tiberghien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor S.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan J.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Minter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-7266","authenticated-orcid":true,"given":"Mark","family":"Carrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"issue":"1","key":"ref1","first-page":"82","article-title":"Human African trypanosomiasis in Working to overcome the global impact of neglected tropical diseases","volume":"1","year":"2010","journal-title":"First WHO report on neglected tropical diseases"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)","volume":"12","author":"PG Kennedy","year":"2013","journal-title":"Lancet Neurol"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrmicro.2017.69","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"15","author":"MC Field","year":"2017","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1179\/2047773213Y.0000000105","article-title":"A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis","volume":"107","author":"P Babokhov","year":"2013","journal-title":"Pathog Glob Health"},{"issue":"5876","key":"ref5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1126\/science.1156296","article-title":"A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in humans","volume":"320","author":"B Vanhollebeke","year":"2008","journal-title":"Science"},{"issue":"6927","key":"ref6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nature01461","article-title":"Apolipoprotein L-I is the trypanosome lytic factor of human serum","volume":"422","author":"L Vanhamme","year":"2003","journal-title":"Nature"},{"issue":"9","key":"ref7","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1016\/S0021-9258(18)83720-6","article-title":"Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein","volume":"264","author":"SL Hajduk","year":"1989","journal-title":"J Biol Chem"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1084\/jem.183.3.1023","article-title":"The main lytic factor of Trypanosoma brucei brucei in normal human serum is not high density lipoprotein","volume":"183","author":"J Raper","year":"1996","journal-title":"J Exp Med"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.75.7.3450","article-title":"Identification of the trypanocidal factor in normal human serum: high density lipoprotein","volume":"75","author":"MR Rifkin","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"ref10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0166-6851(95)00019-W","article-title":"High-density-lipoprotein-independent killing of Trypanosoma brucei by human serum","volume":"70","author":"S Tomlinson","year":"1995","journal-title":"Mol Biochem Parasitol"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4161\/viru.3.1.18295","article-title":"Haptoglobin-hemoglobin receptor independent killing of African trypanosomes by human serum and trypanosome lytic factors","volume":"3","author":"W Bullard","year":"2012","journal-title":"Virulence"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"e1003686","DOI":"10.1371\/journal.ppat.1003686","article-title":"The TgsGP gene is essential for resistance to human serum in Trypanosoma brucei gambiense","volume":"9","author":"P Capewell","year":"2013","journal-title":"PLoS Pathog"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"e1003317","DOI":"10.1371\/journal.ppat.1003317","article-title":"A single amino acid substitution in the group 1 Trypanosoma brucei gambiense haptoglobin-hemoglobin receptor abolishes TLF-1 binding","volume":"9","author":"E DeJesus","year":"2013","journal-title":"PLoS Pathog"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1073\/pnas.1214943110","article-title":"Structure of the trypanosome haptoglobin-hemoglobin receptor and implications for nutrient uptake and innate immunity","volume":"110","author":"MK Higgins","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"37","key":"ref15","doi-asserted-by":"crossref","first-page":"16137","DOI":"10.1073\/pnas.1007074107","article-title":"Mechanism of Trypanosoma brucei gambiense (group 1) resistance to human trypanosome lytic factor","volume":"107","author":"R Kieft","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"e1728","DOI":"10.1371\/journal.pntd.0001728","article-title":"Trypanosoma brucei gambiense group 1 is distinguished by a unique amino acid substitution in the HpHb receptor implicated in human serum resistance","volume":"6","author":"RE Symula","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"7467","key":"ref17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nature12516","article-title":"Mechanism of Trypanosoma brucei gambiense resistance to human serum","volume":"501","author":"P Uzureau","year":"2013","journal-title":"Nature"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0166-6851(94)90172-4","article-title":"The serum resistance-associated (SRA) gene of Trypanosoma brucei rhodesiense encodes a variant surface glycoprotein-like protein","volume":"68","author":"C De Greef","year":"1994","journal-title":"Mol Biochem Parasitol"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0092-8674(00)81706-7","article-title":"A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense","volume":"95","author":"HV Xong","year":"1998","journal-title":"Cell"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pt.2013.03.004","article-title":"Receptor-mediated endocytosis for drug delivery in African trypanosomes: fulfilling Paul Ehrlich\u2019s vision of chemotherapy","volume":"29","author":"S Alsford","year":"2013","journal-title":"Trends Parasitol"},{"issue":"16","key":"ref21","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"JM Lambert","year":"2014","journal-title":"J Med Chem"},{"issue":"7","key":"ref22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"PD Senter","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd3629","article-title":"Brentuximab vedotin","volume":"11","author":"A Younes","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"7578","key":"ref24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature16057","article-title":"Novel antibody-antibiotic conjugate eliminates intracellular S. aureus","volume":"527","author":"SM Lehar","year":"2015","journal-title":"Nature"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1080\/19420862.2016.1229722","article-title":"Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB antibody antibiotic conjugate against Staphylococcus aureus in mice","volume":"8","author":"C Zhou","year":"2016","journal-title":"MAbs"},{"issue":"6","key":"ref26","first-page":"707","article-title":"Chemotherapy of an experimental Trypanosoma cruzi infection with specific immunoglobulin-chlorambucil conjugate","volume":"78","author":"MS Carvalhaes","year":"1998","journal-title":"Lab Invest"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1074\/jbc.M307341200","article-title":"Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm","volume":"279","author":"B Stijlemans","year":"2004","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3389\/fimmu.2017.00724","article-title":"Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis","volume":"8","author":"B Stijlemans","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nm1395","article-title":"Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor","volume":"12","author":"TN Baral","year":"2006","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2014.11.002","article-title":"Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis","volume":"197","author":"JL Arias","year":"2015","journal-title":"J Control Release"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"e1004942","DOI":"10.1371\/journal.ppat.1004942","article-title":"Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis","volume":"11","author":"JD Unciti-Broceta","year":"2015","journal-title":"PLoS Pathog"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jac\/dku393","article-title":"A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis","volume":"70","author":"H Burrell-Saward","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"e2571","DOI":"10.1371\/journal.pntd.0002571","article-title":"Highly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferase","volume":"7","author":"AP McLatchie","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e05553","DOI":"10.7554\/eLife.05553","article-title":"Structural basis for ligand and innate immunity factor uptake by the trypanosome haptoglobin-haemoglobin receptor","volume":"3","author":"H Lane-Serff","year":"2014","journal-title":"Elife"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1038\/ncomms6487","article-title":"Structural basis for trypanosomal haem acquisition and susceptibility to the host innate immune system","volume":"5","author":"K Stodkilde","year":"2014","journal-title":"Nat Commun"},{"key":"ref36","unstructured":"Tiberghien TC, Patel, N.V., Vijayakrishnan, B., Adams, L., Arora, N., Corbett, S., Bertelli, F., Barry, C., Masterson, L., Hartley, J.A., Howard, P.W. Influence of Tether Variations on the Biological Activity of Tesirine Analogues. Poster Abstract: EORTC-NCI-AACR Annual Meeting. 2018;(PB-027):14th November."},{"issue":"14","key":"ref37","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1093\/nar\/gkx521","article-title":"Functional and structural analysis of AT-specific minor groove binders that disrupt DNA-protein interactions and cause disintegration of the Trypanosoma brucei kinetoplast","volume":"45","author":"CR Millan","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejmech.2016.03.064","article-title":"An evaluation of Minor Groove Binders as anti-Trypanosoma brucei brucei therapeutics","volume":"116","author":"FJ Scott","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"JA Hartley","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)","volume":"56","author":"J Mantaj","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref41","first-page":"431","article-title":"The trypanosomiases","author":"PH Holmes","year":"2004"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"e1001226","DOI":"10.1371\/journal.ppat.1001226","article-title":"The killing of African trypanosomes by ethidium bromide","volume":"6","author":"A Roy Chowdhury","year":"2010","journal-title":"PLoS Pathog"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload","volume":"7","author":"AC Tiberghien","year":"2016","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"ref44","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/acs.molpharmaceut.6b00995","article-title":"Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion","volume":"14","author":"N Dimasi","year":"2017","journal-title":"Mol Pharm"},{"issue":"46","key":"ref45","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1016\/j.tetlet.2017.10.010","article-title":"An optimised synthesis of SG3376, a non-cleavable antibody-drug conjugate pyrrolobenzodiazepine drug-linker","volume":"58","author":"AC Tiberghien","year":"2017","journal-title":"Tetrahedron Lett"},{"issue":"23","key":"ref46","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1021\/acs.jmedchem.7b00736","article-title":"Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers","volume":"60","author":"SJ Gregson","year":"2017","journal-title":"J Med Chem"},{"key":"ref47","article-title":"SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads","author":"K Kinneer","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6229","key":"ref48","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1126\/science.aaa4502","article-title":"The in vivo dynamics of antigenic variation in Trypanosoma brucei","volume":"347","author":"MR Mugnier","year":"2015","journal-title":"Science"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.chom.2011.03.013","article-title":"Transmission stages dominate trypanosome within-host dynamics during chronic infections","volume":"9","author":"P MacGregor","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"19","key":"ref50","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"S Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"ref51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"A Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"CM Rudin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref53","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"F Zammarchi","year":"2018","journal-title":"Blood"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"H Donaghy","year":"2016","journal-title":"MAbs"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Monks NR, Schifferli, K.P., Tammali, R., Borrok, M.J., Coats, S. R., Herbst, R., Tice, D.A., and Pore, N. Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies. AACR Annual Meeting 2018;. 2018;April 14\u201318, 2018; Chicago, IL.","DOI":"10.1158\/1538-7445.AM2018-LB-295"},{"issue":"8","key":"ref56","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1535-7163.MCT-16-0825","article-title":"Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4","volume":"16","author":"J Harper","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"ref57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/mp900235k","article-title":"Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor","volume":"7","author":"RJ Boado","year":"2010","journal-title":"Mol Pharm"},{"issue":"2","key":"ref58","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1124\/jpet.111.183483","article-title":"Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration","volume":"339","author":"RB Pepinsky","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"ref59","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/j.1476-5381.2011.01723.x","article-title":"Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier","volume":"165","author":"G Caljon","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"6","key":"ref60","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/00034983.1994.11812911","article-title":"Blood-brain barrier damage in experimental African trypanosomiasis","volume":"88","author":"KA Philip","year":"1994","journal-title":"Ann Trop Med Parasitol"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4269\/ajtmh.2011.10-0487","article-title":"Magnetic resonance imaging to assess blood-brain barrier damage in murine trypanosomiasis","volume":"84","author":"J Rodgers","year":"2011","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"ref62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.actatropica.2008.07.006","article-title":"Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis","volume":"108","author":"JK Thuita","year":"2008","journal-title":"Acta Trop"},{"issue":"9683","key":"ref63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"G Priotto","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"ref64","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1074\/mcp.M114.047647","article-title":"Architecture of a Host-Parasite Interface: Complex Targeting Mechanisms Revealed Through Proteomics","volume":"14","author":"C Gadelha","year":"2015","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"ref65","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1371\/journal.pntd.0002121","article-title":"A cell-surface phylome for African trypanosomes","volume":"7","author":"AP Jackson","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"ref66","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1074\/mcp.M114.045146","article-title":"Cell Surface Proteomics Provides Insight into Stage-Specific Remodeling of the Host-Parasite Interface in Trypanosoma brucei","volume":"14","author":"MM Shimogawa","year":"2015","journal-title":"Mol Cell Proteomics"},{"issue":"6906","key":"ref67","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nature01107","article-title":"A proteomic view of the Plasmodium falciparum life cycle","volume":"419","author":"L Florens","year":"2002","journal-title":"Nature"},{"issue":"23","key":"ref68","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/pmic.201600249","article-title":"PlasmoSEP: Predicting surface-exposed proteins on the malaria parasite using semisupervised self-training and expert-annotated data","volume":"16","author":"Y El-Manzalawy","year":"2016","journal-title":"Proteomics"},{"issue":"4","key":"ref69","article-title":"Trends in Monoclonal Antibody Production","volume":"30","author":"G Dutton","year":"2010","journal-title":"Genetic Engineering & Biotechnology News"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acs.oprd.8b00205","article-title":"Scale-up Synthesis of Tesirine","volume":"22","author":"AC Tiberghien","year":"2018","journal-title":"Organic Process Research and Development"},{"issue":"5","key":"ref71","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","article-title":"Industrialization of mAb production technology: the bioprocessing industry at a crossroads","volume":"1","author":"B Kelley","year":"2009","journal-title":"MAbs"},{"issue":"1","key":"ref72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajur.2016.11.005","article-title":"Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer","volume":"4","author":"ME Pollard","year":"2017","journal-title":"Asian J Urol"},{"issue":"4","key":"ref73","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/btpr.2492","article-title":"Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture","volume":"33","author":"J Pollock","year":"2017","journal-title":"Biotechnol Prog"},{"issue":"3","key":"ref74","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nbt0396-309","article-title":"Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library","volume":"14","author":"TJ Vaughan","year":"1996","journal-title":"Nat Biotechnol"},{"issue":"3","key":"ref75","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jmb.2009.08.032","article-title":"The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators","volume":"393","author":"N Dimasi","year":"2009","journal-title":"J Mol Biol"},{"issue":"6","key":"ref76","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2307\/3282883","article-title":"Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers","volume":"75","author":"H Hirumi","year":"1989","journal-title":"J Parasitol"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0007373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T10:33:25Z","timestamp":1663497205000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0007373"}},"subtitle":[],"editor":[{"given":"Jayne","family":"Raper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":76,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0007373","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/547208","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]}}}